HLA-DQA1 and breast carcinoma: We subsequently confirmed our observations on an independent, clinically similar set of 176 breast cancer cases and showed that high expression of HLA-DQA1 as a single biomarker had a significantly better survival (log-rank p = 0.02) and a trend was seen for high TAP1 as a single biomarker (log-rank p = 0.09).